| Feb.2000
|
Founded Renascience Inc. as an academic bio-venture company in Kanagawa, Japan |
| Sep.2021
|
Listed on the Tokyo Stock Exchange Mothers market (current Growth market, securities code: 4889) |
| Jan.2022
|
Open Tohoku University Renascience Open Innovation Labo (TREx) |
| Aug.2022
|
Initiation of dosing in a PhaseⅢ study of chronic myeloid leukemia |
| Dec.2022
|
Regulatory Approval of Ultrafine Disposable Endoscope |
| Apr.2023
|
Open Hiroshima University Renascience Open Innovation Labo (HiREx) |
| Aug.2023
|
Obtained POC in Phase II study for malignant melanoma |
| Sep.2023
|
Initiation of Phase II Study for Non-Small Cell Lung Cancer |
| Oct.2023
|
Initiation of Phase II study for interstitial lung disease associated with systemic scleroderma |
| Oct.2023
|
Initiation of Phase II Study for Cutaneous Angiosarcoma |
| Jul.2024
|
Initiation of Phase I clinical trial for male pattern baldness (age-related alopecia) by Eirion inc. |
| Sep.2024
|
Rare disease drug designation for malignant melanoma treatment drug |
| Oct.2024
|
Relocated its head office from Nihonbashi, Chuo-ku, Tokyo to Sendai City, Miyagi Prefecture. |
| Feb.2025
|
initiation of the Phase III trial of malignant melanoma treatment drug RS5614 |
| May.2025
|
Top 40 winner of the XPRIZE Healthspan, a global longevity research competition |
| Nov.2025
|
Issuance of new shares and stock acquisition rights through third-party allotment |
